Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

Figure 1

Dose limiting toxicity. In the intra-arterial arm dose limiting toxicity (DLT) was observed in two of three patients at 50 mCi in the first cohort and in none of the three patients each in both the second cohort (45 mCi) and the third cohort (50 mCi). In the intravenous arm, one out of three patients experienced DLT at 50 mCi and none out of the three patients each in the second (50 mCi) and third cohorts (75 mCi) suffered a DLT. In summary, 2/6 patients experienced DLT in the intra-arterial arm (MTD reached at 50 mCi) and 1/6 patients in the intravenous arm (MTD not reached).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us